Summary The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …

Our incomplete understanding of the causes and pathways involved in the onset and
progression of multiple sclerosis (MS) limits our ability to effectively treat this complex …

Multiple sclerosis (MS) lesions that do not resolve in the months after they form harbour
ongoing demyelination and axon degeneration, and are identifiable in vivo by their …

Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …

Remyelination, the myelin regenerative response that follows demyelination, restores
saltatory conduction and function and sustains axon health. Its declining efficiency with …

Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine
kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which …

We sought to define the pathological features of myelin oligodendrocyte glycoprotein (MOG)
antibody associated disorders (MOGAD) in an archival autopsy/biopsy cohort. We …

Neurological disorders are the leading cause of physical and cognitive disability across the
globe, currently affecting approximately 15% of the worldwide population [1]. Absolute …

Recent data suggest that multiple sclerosis white matter lesions surrounded by a rim of iron
containing microglia, termed iron rim lesions, signify patients with more severe disease …

In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …